English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 45422/58598 (78%)
造訪人次 : 2535817      線上人數 : 274
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋


    請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/6446


    題名: Warfarin與銀杏葉萃取物(EGb 761)交互作用之評估
    Evaluation of the Interaction between Warfarin and Ginkgo biloba extract (EGb 761)
    作者: 賴佳楓
    ChiaFeng Lai
    貢獻者: 藥學研究所
    關鍵詞: 瓦法靈
    銀杏葉萃取物
    交互作用
    Warfarin
    Ginkgo biloba extract
    EGb 761
    Interaction
    日期: 2002
    上傳時間: 2009-09-11 16:55:39 (UTC+8)
    摘要: 中草藥的使用愈趨廣泛，因此在探討中草藥與西藥合併使用後，是否會產生交互作用就成為重要課題。目前已有6個因服用銀杏葉萃取物而造成出血之臨床案例報告，其中一例為病人併服warfarin後產生。因此本研究以下列3項結果評估Warfarin與標準規格之銀杏葉萃取物(EGb 761)的交互作用存在與否，並確立EGb 761在血液學上的安全性；以做為臨床醫療人員及研究者解決此一課題的基礎：(1)大白鼠模式下，看EGb 761對warfarin藥物動力學及臨床監測參數PT、INR值的影響(2)收集臨床實例分析EGb 761對warfarin監測參數INR數值的影響(3)利用健康志願受試者服用EGb 761觀察凝血功能檢驗數值(platelet counts, INR, bleeding time, clotting time)之變化。藥物動力學多重劑量模式下，EGb 761明顯降低warfarin濃度曲線下面積(AUC)、增加清除率(CL/F)及分佈體積(Vd/F)；相同的，最大PT值及PT曲線下面積在EGb 761存在下之結果亦明顯降低。共21個臨床實例之分析結果顯示EGb 761對已服用warfarin病患之INR值影響並無影響。而12位健康受試者在連續服用臨床治療建議劑量下之EGb 761(120 mg/d) 28天，所有凝血功能指標變化皆未達到臨床上意義。因此治療建議劑量下之EGb 761不會干擾正常人凝血功能；但因為在大白鼠模式下觀察到長期服用高劑量之EGb 761對warfarin存在有藥物動力學交互作用及對warfarin臨床監測參數PT、INR值有下降之影響，所以在產生交互作用機制尚未確定及無完整人體臨床試驗結果報告之情況下；建議在二藥併用後密切監測PT、INR是必須的。
    The potential herb-drug interaction should be screened since the usage of herbal products became popular. Six bleeding cases have been reported with the use of Ginkgo biloba extract, and one was linked to concurrent use of warfarin. The objective of the study was to evaluate the effect of EGb 761, a standardized Ginkgo biloba extract, on warfarin and coagulation function. To recognize the influence of EGb 761 on pharmacokinetics and pharmacodynamics of warfarin, changes in warfarin plasma concentration and prothrombin time (PT) after coadministration with EGb 761 were studied in a Sprague Dawley model. Clinical cases with concurrent use of two drugs were also retrospectively reviewed to evaluate the relationship between EGb 761 and international normalized ratio (INR). Changes of coagulation parameters, including platelet counts, INR, bleeding time, clotting time, was determinated in twelve healthy volunteers taking EGb 761 120 mg once daily for 28 days. A significant decrease in the area under plasma concentration-time curves (AUC) from 22.54±2.67 to 17.27±1.64 μg·hr/ml, was detected with coadministration of EGb 761 under a multiple dosing design (p=0.002). Similarly, maximal PT and area under the PT versus time curve were significantly reduced with EGb 761 treatment group (p=0.001). There was no significant change in INR after adding EGb 761 in 21 clinical cases (p=0.551). No clinically significant change in coagulation parameters was observed when finishing the regimen. No clinically significant influence of EGb 761 on warfarin was found on clinical cases and healthy volunteers. As the animal results of decreased pharmacokinetic and pharmacodynamic effects of warfarin, careful monitoring of PT was recommended with concurrent use of EGb 761 and warfarin.
    資料類型: thesis
    顯示於類別:[藥學系] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    摘要.doc28KbMicrosoft Word197檢視/開啟
    摘要.pdf750KbAdobe PDF730檢視/開啟
    摘要.ppt158KbMicrosoft Powerpoint178檢視/開啟
    摘要.ps498KbPostscript94檢視/開啟


    在TMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    著作權聲明 Copyright Notice

    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏，包含體系內各式學術著作及學術產出。秉持開放取用的精神，提供使用者進行資料檢索、下載與取用，惟仍請適度、合理地於合法範圍內使用本平台之內容，以尊重著作權人之權益。商業上之利用，請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台，視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例，並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者，煩請權利人通知本平台維護人員([email protected])，將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋